COMMUNIQUÉS West-GlobeNewswire

PacBio Announces Third Quarter 2025 Financial Results
05/11/2025
MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025 Q3 2024 Revenue $38.4 million $40.0 [...]
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress
05/11/2025
Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated RASolute [...]
HealthEquity Announces Third Quarter Earnings Date
05/11/2025
DRAPER, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest Health Savings Accounts (“HSA") and consumer-directed benefits administrator, [...]
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
05/11/2025
IMCIVREE now publicly covered for weight management due to Bardet-Biedl syndrome (BBS) in Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and under NIHB BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm [...]
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
05/11/2025
IMCIVREE est désormais remboursé pour le cadre de la gestion du poids chez les patients atteints du syndrome de Bardet-Biedl (BBS) en Ontario, en Alberta, en Colombie-Britannique, en Saskatchewan, en Nouvelle-Écosse et [...]
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the [...]
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
05/11/2025
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
05/11/2025
Claseprubart achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL), Quantitative Myasthenia Gravis (QMG), and other efficacy measures at Week [...]
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
05/11/2025
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings [...]
Tarsus to Participate in Upcoming Investor Conference
05/11/2025
IRVINE, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in a fireside chat at the Guggenheim 2 nd Annual Healthcare Innovation [...]
Benitec Biopharma Inc. Announces Proposed Public Offering
05/11/2025
HAYWARD, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines [...]
Novo Nordisk Wegovy® users achieved waist and BMI targets linked to improved health and low risk of obesity-related complications
05/11/2025
Unlike many other diseases, there are no set guidelines on treatment targets for obesity, and outcomes often rely on percentage weight loss only Body mass index (BMI) and waist-to-height ratio (a measurement of [...]
STERIS Announces Financial Results for Fiscal 2026 Second Quarter
05/11/2025
Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9% As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47 Fiscal 2026 constant [...]
BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025
05/11/2025
MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) , a regenerative medicine innovator focused on stem cell-based therapies and [...]
PharmaCorp Announces C$15 Million Bought Deal Public Offering
05/11/2025
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+ NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE [...]
SCYNEXIS Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
SCYNEXIS to receive one-time payments totalling $24.8 million from GSK as part of the resolution of the disagreement related to the restart of the Phase 3 MARIO study in invasive candidiasis. Scynexis agreed to GSK’s [...]
Genelux Corporation Reports Third Quarter 2025 Financial Results and Provides General Business Updates
05/11/2025
-- Lung cancer programs progressing with interim data updates expected in Q4 2025 -- -- Topline data from OnPrime Phase 3 ovarian cancer registrational trial expected in the second half of 2026 -- -- Cash, cash [...]
Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results
05/11/2025
Ongoing Phase 1 trial of CTIM-76 (CLDN6 x CD3) demonstrates encouraging antitumor activity and safety Ongoing Phase 1 trial of CT-95 (MSLN x CD3) is approaching target dose levels Cash and cash equivalents of $76.9 [...]
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
05/11/2025
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission for U.S. [...]

Pages